Jun 22, 2020
LUNGevity and EGFR Resisters Collaborate on Lung Cancer Research Awards
May 29, 2020
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Mar 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
Mar 19, 2020
Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer
Feb 26, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Dec 13, 2019
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Nov 13, 2019
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Nov 12, 2019
Breckenridge Announces Final Approval of ANDA for Erlotinib Hydrochloride Tablets (generic for Tarceva®)
Oct 07, 2019
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
Sep 10, 2019
Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Aug 05, 2019
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Jun 03, 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Reimbursement Coverage in Japan
May 31, 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
May 29, 2019
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
May 15, 2019
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
May 10, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets
Feb 26, 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Dec 28, 2018
InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer
Dec 18, 2018
Emerging Medical Device Market Expected to Exceed $400 Billion by 2023
Oct 18, 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer